The prevalence of multi-drug tuberculosis is increasing worldwide making the search for new anti-tuberculosis drugs imperative. A greater understanding of the basic biochemistry of M. tuberculosis will greatly facilitate this process. The overall objective of this proposal is to identify drug targets relating to cell wall synthesis in M. tuberculosis, characterize the enzymes involved and identify lead compounds for drug development. This project (3) focuses on the role played by the enzymes involved in isoprenoid biosynthesis. Isoprenoid biosynthesis can be considered one of the earliest steps in cell wall synthesis making it an ideal potential drug target. Isoprenoid compounds such as polyprenyl phosphate, menaquinone and possibly hopanoids play crucial and in some cases essential roles in mycobacterial metabolism. The observation that M. tuberculosis is susceptible to the topical antibiotic bacitracin, which inhibits isoprenoid biosynthesis demonstrates that the synthesis of the isoprenoid compounds is required for the survival of M. tuberculosis. Many bacterial isoprenoids are structurally distinct from those found in eukaryotes yet little is known about the biosynthesis of these compounds in M. tuberculosis. It was originally assumed that prokaryotes use the same biosynthetic pathways as eukaryotes for the synthesis of isoprenoids This assumption has recently been shown to be correct. We believe that identification and characterization of enzymes involved in unique and essential biosynthetic pathways will lead to the development of novel drugs for the treatment of tuberculosis. With that in mind, we have developed the following project in which we will attempt to: 1) identify compounds that inhibit 1-deoxyxylulose-5-phosphate synthase (DXS), an enzyme essential for bacterial isoprenoid biosynthesis that is not found in mammals, using a medium to high throughput assay. 2) Characterize the portions of the isoprenoid biosynthetic pathway that are unique to mycobacteria.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI046393-03
Application #
6495061
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2001-09-01
Project End
2002-08-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
112617480
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Amin, Anita G; Angala, Shiva K; Chatterjee, Delphi et al. (2009) Rapid screening of inhibitors of Mycobacterium tuberculosis growth using tetrazolium salts. Methods Mol Biol 465:187-201
Wang, Wenjian; Dong, Changjiang; McNeil, Michael et al. (2008) The structural basis of chain length control in Rv1086. J Mol Biol 381:129-40
Parish, Tanya; Schaeffer, Merrill; Roberts, Gretta et al. (2005) HemZ is essential for heme biosynthesis in Mycobacterium tuberculosis. Tuberculosis (Edinb) 85:197-204
Schaeffer, M L Merrill L; Carson, J D Jeffrey D; Kallender, Howard et al. (2004) Development of a scintillation proximity assay for the Mycobacterium tuberculosis KasA and KasB enzymes involved in mycolic acid biosynthesis. Tuberculosis (Edinb) 84:353-60
Brennan, P J (2003) Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) 83:91-7
Ma, Y; Stern, R J; Scherman, M S et al. (2001) Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob Agents Chemother 45:1407-16
Escuyer, V E; Lety, M A; Torrelles, J B et al. (2001) The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem 276:48854-62